NASDAQ:HTGM

HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$5.01
$6.80
52-Week Range
N/A
Volume
773,040 shs
Average Volume
294,806 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HTGM stock logo

About HTG Molecular Diagnostics Stock (NASDAQ:HTGM)

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

HTGM Stock News Headlines

HTGMQ HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics Inc HTGMQ
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
HTG Molecular Diagnostics Inc (HTGMQ)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
HTGM HTG Molecular Diagnostics, Inc.
See More Headlines
Receive HTGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:HTGM
Employees
84
Year Founded
N/A

Profitability

Net Income
$-21,590,000.00
Net Margins
-324.25%
Pretax Margin
-324.05%

Debt

Sales & Book Value

Annual Sales
$6.37 million
Book Value
$2.44 per share

Miscellaneous

Free Float
2,156,000
Optionable
Optionable
Beta
0.99
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • John L. Lubniewski
    President, Chief Executive Officer & Director
  • Shaun D. McMeans
    CFO, Secretary, Treasurer & SVP-Administration
  • Byron T. Lawson
    Chief Commercial Officer & Senior Vice President
  • Laura L. Godlewski
    Chief Accounting Officer & Vice President-Finance
  • Sam M. Rua
    Senior VP-Regulatory Affairs & Quality Systems

HTGM Stock Analysis - Frequently Asked Questions

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) issued its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to analyst estimates of $2.90 million. HTG Molecular Diagnostics had a positive trailing twelve-month return on equity of 45.52% and a negative net margin of 324.25%. During the same period last year, the company earned ($1.05) EPS.

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

HTG Molecular Diagnostics (HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

This page (NASDAQ:HTGM) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners